Ahead of Enea's Q3 report on 23 October 2025, Redeye is raising its network estimate, buoyed by a ne...
Redeye provides a short comment on the recently announced Q3 sales figure from Scandinavian ChemoTec...
* Report out on 17 October * Q3e sales SEK 48m, EBIT SEK -0.
Redeye comments on Isofol’s update that the second dose level in its ongoing phase Ib/II study has b...
Redeye leaves a short comment on CLS’s fully subscribed warrants program (TO8B).
* Byggmästaren proposes extraordinary dividend and share split * Updates dividend policy and reaffir...
Redeye comments on Heliospectra’s proposed SEK49.5m rights issue, partly secured by main shareholder...
* Solid autumn intake * Sonans back on track * Fair value range of NOK 14-25 Solid autumn intake To...
* We expect an uneventful Q3 * Q3e net sales of SEK 179m, EBITA of SEK 29m * We reiterate our SEK 36...
* We forecast 7% EBITA growth in Q3'25 * M&A could add 30-40% to '27e EBITA * We raise our fair valu...
Redeye comments on Invisio’s announcement of a 10-year contract with US Coast Guard regarding wirele...
Redeye returns with an update on Saniona. We are impressed by the company’s deal-making capabilities...
Redeye comments on Glenn Paxman’s ownership reduction.
Redeye leaves Addnode’s CMD with a positive impression, as the company’s ambition for growth and mar...
Redeye provides a brief comment on Scibase receiving an initial order valued at approximately SEK8m ...
Redeye provides an update following the company’s Q2 report, which demonstrated significant sequenti...
Redeye updates its estimates for Relais’ recent hybrid bond issue.
Redeye believes the data is solid and in line with previous readouts.
Bioteknikbolaget Aptahem, som utvecklar läkemedelskandidaten Apta-1 mot sepsis, har tagit ett strate...
After announcing the proposed rights issue, we update our Base Case, including the number of shares.
